肾移植非劣效性试验的设计与报告质量:系统综述
该系统综述检索至2025年2月的随机对照非劣效性试验,共纳入43项肾移植试验。结果显示65%的研究未论证非劣效性界值,77%未说明缺失数据处理方法,28%结论不正确,设计和报告质量随时间改善但与期刊影响因子或申办方类型无关。
要点
- 多数肾移植非劣效性试验的界值未论证或论证不充分,可能导致劣效疗法被采纳。
- 缺失数据处理和主要分析(如仅用ITT)报告不足,影响试验解释。
- 设计和报告质量随时间改善,但与期刊影响因子或申办方类型无关。
核心结论
- 肾移植非劣效性试验在设计、实施和报告方面存在重大缺陷。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Cochrane对照试验中心注册库,纳入截至2025年2月发表的肾移植随机对照非劣效性试验,共43项。
主要发现
- 43项试验中,36项(84%)比较新型免疫抑制方案与标准治疗,26项(60%)由企业资助。
- 28项(65%)研究未论证非劣效性界值,7项(16%)论证不充分。
- 32项具有分类主要结局的研究中,30项(94%)评估绝对风险降低而非相对风险。
- 33项(77%)未说明缺失数据处理方法,24项(56%)仅用意向性分析确定主要疗效。
- 12项(28%)研究结论不正确,多在不满足非劣效性时声称等效。
临床怎么用
- 解读肾移植非劣效性试验时,应关注非劣效性界值是否预先论证及缺失数据处理是否充分。
- 临床采纳非劣效性结论前,需确认试验未错误声称等效且分析方法恰当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Many kidney transplant noninferiority trials used unjustified or overly generous margins, risking adoption of inferior therapies. Inadequate analyses, poor missing data handling, and weak Consolidated Standards of Reporting Trials (CONSORT) adherence limit trial interpretation. Stronger noninferiority trial design and reporting are needed to improve evidence quality in kidney transplantation. BACKGROUND: Noninferiority trials are essential in kidney transplantation, where established standard-of-care treatments make placebo-controlled designs infeasible, and their use is increasing. We aimed to assess the design and reporting quality of noninferiority trials in kidney transplantation, specifically assessing adherence to existing guidelines. METHODS: We searched medical literature analysis and retrieval system online, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled noninferiority trials in kidney transplantation published up to February 2025. Two investigators reviewed and extracted data. Study quality was assessed regarding design and reporting quality using key noninferiority design criteria and the Consolidated Standards of Reporting Trials 2012 extension, respectively. RESULTS: We identified 43 unique trials: 36 (84%) compared a novel immunosuppressive regimen to standard of care and 26 (60%) were industry sponsored. The noninferiority margin (the worst-case loss in efficacy considered clinically acceptable) was not justified in 28 (65%) studies and poorly justified in seven (16%). Of 32 studies with a categorical primary outcome, 30 (94%) assessed absolute risk reduction rather than relative risk. Most studies had high withdrawal and dropout rates, yet 33 (77%) did not specify methods for handling missing data. Intention-to-treat analysis alone was used to determine primary efficacy in 24 (56%) studies. Twelve studies (28%) provided an incorrect conclusion, most claiming equivalence when noninferiority had not been adequately demonstrated. Both design and reporting quality have improved over time ( P = 0.02, P = 0.002, respectively). No association was evident between design or reporting quality and journal impact factor or sponsor type. CONCLUSIONS: We found major deficiencies in the design, conduct, and reporting of noninferiority trials in kidney transplantation.
引用
- Shi B, Bleasel JM, Ying T, et al. Design and Reporting Quality of Noninferiority Trials in Kidney Transplantation: A Systematic Review. J Am Soc Nephrol. 2026. PMID: 41739578. doi:10.1681/ASN.0000001041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。